IceCure Medical Completes Five-Year Follow-Up Study in Kidney Cancer Cryoablation
IceCure Medical completed its five-year follow-up study evaluating long-term safety and local tumor control after kidney cancer cryoablation using its proprietary system. The milestone provides the dataset needed for planned regulatory submissions in Europe and the U.S. during 2026.
1. Study Completion and Scope
IceCure Medical has completed the five-year clinical follow-up of its proprietary cryoablation system in kidney cancer patients, capturing long-term safety data and local control outcomes. The study’s endpoints include recurrence rates, adverse event profiles, and durability of tumor ablation over five years.
2. Regulatory and Commercial Implications
With data collection concluded, IceCure plans to analyze results and prepare submissions to European notified bodies and the U.S. FDA for expanded market access. Approval milestones in H2 2026 could drive commercialization and revenue growth for its cryoablation platform.